Canfield

Researchers are investigating how an amylopectin chromium blend affects whole-body protein balance in peri- and post-menopausal women, a time when hormonal changes can negatively impact protein metabolism and muscle health. The study aims to determine whether this supplement supports positive protein balance and if a concentrated dose offers additional benefits. The research uses a randomized, double-blind, placebo-controlled design to compare the blend against a placebo (amylopectin alone) in women aged 40 to 65 years. Participants will be randomly assigned to one of three groups: a standard dose of amylopectin-chromium blend (2 g) with 20 g of protein from yogurt, a concentrated dose of the blend (100 mg) with 20 g of protein, or a placebo of amylopectin (2 g) with 20 g of protein. Each participant will receive only one dose during the study, following a short resistance exercise session. The study includes four in-person visits over 2-3 weeks, including screening, baseline assessments, exercise familiarization, and the intervention day. During the study, participants will follow a controlled diet and avoid caffeine, alcohol, and strenuous exercise before visits. Researchers will measure whole-body protein synthesis and breakdown using tracer methods and collect 24-hour urine samples and blood tests. Continuous glucose monitoring will assess glucose control over 24 hours. Safety monitoring includes vital signs and adverse event tracking. The total blood collected will be about 38 mL. This study may provide valuable insights into nutritional strategies to support muscle and metabolic health during midlife in women.

Researchers are evaluating the effects of citicoline on mood in healthy men and women aged 21 to 65 years. This 4-week study is designed as a randomized, double-blind, placebo-controlled trial to compare citicoline supplementation with a placebo. The goal is to determine whether taking citicoline improves mood using both subjective and objective mood assessments. Participants will be randomly assigned to receive either oral citicoline or a matching placebo during the study period. The study involves daily intake of the assigned supplement over four weeks while maintaining usual diet, caffeine, and physical activity habits. The trial is designed to carefully monitor mood changes and ensure consistent treatment conditions. During the trial, participants will undergo cognitive assessments and complete mood questionnaires to measure Total Mood Disturbance using a validated scale after 4 weeks. Researchers will collect medical history, routine blood chemistries, blood pressure, and heart rate measurements. Participants are asked to continue their usual lifestyle patterns, and safety will be monitored throughout the study duration.